These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 9408818)

  • 1. Prolongation of clozapine-induced granulocytopenia associated with olanzapine.
    Flynn SW; Altman S; MacEwan GW; Black LL; Greenidge LL; Honer WG
    J Clin Psychopharmacol; 1997 Dec; 17(6):494-5. PubMed ID: 9408818
    [No Abstract]   [Full Text] [Related]  

  • 2. Olanzapine prolongation of granulocytopenia after clozapine discontinuation.
    Konakanchi R; Grace JJ; Szarowicz R; Pato MT
    J Clin Psychopharmacol; 2000 Dec; 20(6):703-4. PubMed ID: 11106146
    [No Abstract]   [Full Text] [Related]  

  • 3. Olanzapine: safe during clozapine-induced agranulocytosis.
    Oyewumi LK; Al-Semaan Y
    J Clin Psychopharmacol; 2000 Apr; 20(2):279-81. PubMed ID: 10770478
    [No Abstract]   [Full Text] [Related]  

  • 4. Olanzapine treatment after clozapine-induced granulocytopenia in 3 patients.
    Swartz JR; Ananth J; Smith MW; Burgoyne KS; Gadasally R; Arai Y
    J Clin Psychiatry; 1999 Feb; 60(2):119-21. PubMed ID: 10084639
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Experiences with clozapine and olanzapine.
    Chatterton R
    Aust N Z J Psychiatry; 1998 Jun; 32(3):463. PubMed ID: 9672741
    [No Abstract]   [Full Text] [Related]  

  • 6. Olanzapine after clozapine: the rare case of prolongation of granulocytopaenia.
    Lambert T
    Aust N Z J Psychiatry; 1998 Aug; 32(4):591-2. PubMed ID: 9711381
    [No Abstract]   [Full Text] [Related]  

  • 7. Granulocyte colony-stimulating factor plasma levels during clozapine- and olanzapine-induced granulocytopenia.
    Schuld A; Kraus T; Hinze-Selch D; Haack M; Pollmächer T
    Acta Psychiatr Scand; 2000 Aug; 102(2):153-5. PubMed ID: 10937789
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Agranulocytosis and neutropenia with typical and atypical neuroleptics.
    Hong X; Wang X
    Am J Psychiatry; 2001 Oct; 158(10):1736-7. PubMed ID: 11579015
    [No Abstract]   [Full Text] [Related]  

  • 9. Olanzapine-induced agranulocytosis.
    Naumann R; Felber W; Heilemann H; Reuster T
    Lancet; 1999 Aug; 354(9178):566-7. PubMed ID: 10470705
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Olanzapine-induced agranulocytosis: a case report and review of the literature.
    Tolosa-Vilella C; Ruiz-Ripoll A; Mari-Alfonso B; Naval-Sendra E
    Prog Neuropsychopharmacol Biol Psychiatry; 2002 Feb; 26(2):411-4. PubMed ID: 11817522
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Olanzapine-induced neutropenia in patients with history of clozapine treatment: two case reports from a state psychiatric institution.
    Teter CJ; Early JJ; Frachtling RJ
    J Clin Psychiatry; 2000 Nov; 61(11):872-3. PubMed ID: 11105743
    [No Abstract]   [Full Text] [Related]  

  • 12. Olanzapine for treatment-refractory psychosis in patients responsive to, but intolerant of, clozapine.
    Weiss EL; Longhurst JG; Bowers MB; Mazure CM
    J Clin Psychopharmacol; 1999 Aug; 19(4):378-80. PubMed ID: 10440469
    [No Abstract]   [Full Text] [Related]  

  • 13. Massive increase in serum creatine kinase during olanzapine and quetiapine treatment, not during treatment with clozapine.
    Boot E; de Haan L
    Psychopharmacology (Berl); 2000 Jun; 150(3):347-8. PubMed ID: 10923763
    [No Abstract]   [Full Text] [Related]  

  • 14. [Atypical antipsychotics].
    Heeringa M; van Grootheest AC
    Ned Tijdschr Geneeskd; 2000 Oct; 144(43):2078-9. PubMed ID: 11072513
    [No Abstract]   [Full Text] [Related]  

  • 15. Weight gain and antipsychotic medications.
    Aquila R; Emanuel M
    J Clin Psychiatry; 1999 May; 60(5):336-7. PubMed ID: 10362443
    [No Abstract]   [Full Text] [Related]  

  • 16. Predicting drug-induced agranulocytosis: characterizing neutrophil-generated metabolites of a model compound, DMP 406, and assessing the relevance of an in vitro apoptosis assay for identifying drugs that may cause agranulocytosis.
    Iverson S; Zahid N; Uetrecht JP
    Chem Biol Interact; 2002 Nov; 142(1-2):175-99. PubMed ID: 12399162
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recurrent priapism during treatment with clozapine and olanzapine.
    Compton MT; Saldivia A; Berry SA
    Am J Psychiatry; 2000 Apr; 157(4):659. PubMed ID: 10777416
    [No Abstract]   [Full Text] [Related]  

  • 18. The effects of risperidone and olanzapine on the indications for clozapine.
    Ganguli R; Brar JS
    Psychopharmacol Bull; 1998; 34(1):83-7. PubMed ID: 9564203
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Olanzapine-induced neutropenia after clozapine-induced neutropenia.
    Benedetti F; Cavallaro R; Smeraldi E
    Lancet; 1999 Aug; 354(9178):567. PubMed ID: 10470706
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Six-month review of weight and metabolic parameters in patients receiving clozapine, risperidone, olanzapine, or quetiapine.
    Kelly DL; Kreyenbuhl J; Love RC; Van-Duong Q; Conley RR
    J Clin Psychiatry; 2003 Sep; 64(9):1133-4. PubMed ID: 14628994
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.